Navigation Links
European researchers harness unique properties of boron to develop new drugs and diagnostics
Date:10/21/2008

Researchers are on the verge of unleashing the power of the element boron in a new generation of drugs and therapies, as decades of research begins to bear fruit. Boron has to date far been one of biology's best kept secrets, but is now attracting fast growing research interest and investment from the pharmaceutical industry in the quest for novel drugs to tackle cancer and infectious diseases, potentially overcoming limitations and side effects of current products.

Europe's response to the challenges and opportunities of boron chemistry in medicine was discussed at a recent workshop, Biobor Exploring New Opportunities Of Boron Chemistry Towards Medicine. According to its convenor Zbigniew Lesnikowski, the ESF workshop set the stage for a new era of boron therapies going beyond the current application in cancer radiotherapy via boron neutron capture therapy (BNCT), in which the element is used to help translate beams of neutrons into radiation that targets tumour cells with less "collateral damage" of surrounding healthy tissue.

"Yes, it became obvious during the workshop that there is now sufficient knowledge and enough compounds to support a broad program of screening in the quest for new antiviral and anticancer drugs containing essential boron components," said Lesnikowski. There was also scope for improving the application of BNCT to cancer, but besides these two therapeutic avenues, boron also has vast potential as the basis for compounds in diagnosis and biosensing, and also for novel bioorganic materials, said Lesnikowski.

The applications in bio sensing, biomaterials, and drug development all spring from the fundamental chemical properties of boron. All life is derived ultimately from the element carbon, which lies next to boron in the periodic table of elements, their respective atomic numbers being six and five. Boron compounds share some similarities with carbon but also have important differences. It is the combinatio
'/>"/>

Contact: Zbigniew Lesnikowski
zlesnikowski@cbm.pan.pl
48-422-723-629
European Science Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Last chance for media to register for ECCO 14 -- the European Cancer Conference
2. 2 French scientists win European award for communication
3. Three-way mating game of North American lizard found in distant European relative
4. European lead in reading past climates from ice cores
5. Hot spots the key to controlling European carp in Australia
6. IdentiPHI Opens Paris Office to Boost European Sales and Support
7. European Union forests expanding, absorbing carbon at surprisingly high rate: study
8. First European Lung Cancer Conference
9. ESFs European ice core project EPICA receives prestigious Descartes Prize
10. European membrane expertise to focus on new treatments for human diseases
11. European light research opens door for optical storage and computing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... Gothenburg, Sweden: Individual results of genetic research studies ... a scientist will tell the annual conference of the ... Robin Hayeems, from the Department of Health Policy, Management ... say that she believes that the view held by ...
... small genetic change can predict how people infected with ... personalised therapy for this difficult to treat disease, the ... will hear today (Sunday 13 June). Dr. ... of Lausanne, Switzerland, will tell delegates that individuals with ...
... Biochemistry and Molecular Biology (ASBMB) has announced that ... the Cleveland Clinic,s Lerner Research Institute and emeritus ... is the recipient of the society,s 2011 Herbert ... The lectureship recognizes outstanding lifetime scientific ...
Cached Biology News:Should the results of individual genetic studies be disclosed to participants? 2Should the results of individual genetic studies be disclosed to participants? 3Small genetic variant can predict response to hepatitis C treatment 2Small genetic variant can predict response to hepatitis C treatment 3Dr. George Stark receives 2011 Herbert Tabor/Journal of Biological Chemistry Lectureship from ASBMB 2
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... , , VENLO, The Netherlands, Aug. 4 QIAGEN ... 2009 financial results call. The Webcast will take place at 9:30 a.m. EDT on ... Executive Officer, and Roland Sackers, Chief Financial Officer. , , ... financial results call, When: 9:30 a.m. EDT ...
... 4 Zeus, Inc., a global leader in material science ... with the hiring of David Labelle as its new Business ... Sales Supervisor. Both Labelle and Ramsey have strong backgrounds in ... , David Labelle, who lives in Lyon, France, ...
... , , MINNEAPOLIS, Aug. 4 ... Directors has decided to pay a dividend of $0.25 per share for ... payable August 31, 2009 to all common shareholders of record on August ... of Directors on a quarterly basis. , , Techne ...
Cached Biology Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11 2Zeus Expands International Support With New Hires 2
TRBP1 Antibody...
Complete cell culture media with cytokines...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: